Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 8(91), p. 1561-1565, 2004

DOI: 10.1038/sj.bjc.6602200

Links

Tools

Export citation

Search in Google Scholar

Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

Journal article published in 2004 by YC; Hsu-C; Chen JY; Cheng AL Shen, Y.-C.; Hsu C.; Chen J. Y.; Cheng A. L. Shen, C. Hsu ORCID, J.-Y. Chen, A.-L. Cheng
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Although the PPARg agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1–10 mM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid. Furthermore, no synergistic effect was found between troglitazone and cytotoxic anticancer agents. ; 醫院行政單位 ; 醫學院附設醫院 ; 期刊論文